Drug intelligence / Profile preview

SuppoCan

Development stage: Unknown
Lead developer: Incannex Healthcare
Modality: Small Molecules
Administration: Rectal

Overview

SuppoCan is a cannabinoid-based pharmaceutical therapeutic developed by APIRx Pharmaceuticals USA, which was acquired by Incannex Healthcare. It is formulated as a suppository and is currently in development for gastrointestinal conditions, specifically Inflammatory Bowel Disease (IBD). APIRx specializes in producing cannabinoid active pharmaceutical ingredients (APIs) from natural extracts of the cannabis sativa plant under cGMP conditions.

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on SuppoCan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SuppoCan.

Explore the full profile